WVE (Wave Life Sciences Ltd. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by WVE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Aik Na Tan | Director | Sell | — | — |
| 2026-08-13 | Heidi L Wagner | Director | MIXED | — | — |
| 2026-08-13 | Adrian Rawcliffe | Director | Sell | — | — |
| 2026-08-13 | KEN TAKANASHI | Director | Sell | — | — |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | — | — |
| 2026-03-26 | KEN TAKANASHI | Director | C | — | — |
| 2026-02-27 | Chris Francis | See Remarks | MIXED | — | — |
| 2026-02-11 | Kyle Moran | Chief Financial Officer | MIXED | — | — |
| 2026-02-11 | PAUL BOLNO | President and CEO | MIXED | — | — |
| 2026-02-11 | Chris Francis | See Remarks | MIXED | — | — |
| 2026-02-11 | Chandra Vargeese | See Remarks | MIXED | — | — |
| 2026-01-06 | Chris Francis | See Remarks | MIXED | — | — |
| 2025-12-15 | GSK plc | 10%+ Owner | Buy | — | — |
| 2025-12-10 | Gregory L. Verdine | Director | Sell | — | — |
| 2025-12-10 | MARK CORRIGAN | Director | Sell | — | — |
| 2025-12-10 | Heidi L Wagner | Director | MIXED | — | — |
| 2025-12-10 | Adrian Rawcliffe | Director | MIXED | — | — |
| 2025-12-10 | Kyle Moran | Chief Financial Officer | MIXED | — | — |
| 2025-12-10 | Chris Francis | See Remarks | MIXED | — | — |
| 2025-12-10 | Aik Na Tan | Director | MIXED | — | — |
| 2025-12-10 | CHRISTIAN O HENRY | Director | MIXED | — | — |
| 2025-11-14 | Adrian Rawcliffe | Director | Sell | — | — |
| 2025-11-14 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2025-08-26 | PAUL BOLNO | President and CEO | Sell | — | — |
| 2025-08-26 | Gregory L. Verdine | Director | Sell | — | — |
| 2025-08-19 | Aik Na Tan | Director | MIXED | — | — |
| 2025-08-13 | KEN TAKANASHI | Director | A | — | — |
| 2025-08-13 | Aik Na Tan | Director | A | — | — |
| 2025-08-13 | Heidi L Wagner | Director | A | — | — |
| 2025-08-13 | Adrian Rawcliffe | Director | A | — | — |
| 2025-08-13 | MARK CORRIGAN | Director | A | — | — |
| 2025-08-13 | Gregory L. Verdine | Director | A | — | — |
| 2025-08-13 | CHRISTIAN O HENRY | Director | MIXED | — | — |
| 2025-08-13 | Rajeev M. Shah | Director | A | — | — |
| 2025-08-07 | KEN TAKANASHI | Director | Sell | — | — |
| 2025-08-07 | Aik Na Tan | Director | Sell | — | — |
| 2025-06-13 | Gregory L. Verdine | Director | Sell | — | — |
| 2025-03-21 | CHRISTIAN O HENRY | Director | MIXED | — | — |
| 2025-03-07 | PAUL BOLNO | President and CEO | MIXED | — | — |
| 2025-03-07 | Gregory L. Verdine | Director | M | — | — |
| 2025-03-05 | Chandra Vargeese | See Remarks | M | — | — |
| 2025-02-06 | Chandra Vargeese | See Remarks | A | — | — |
| 2025-02-06 | PAUL BOLNO | President and CEO | A | — | — |
| 2025-02-06 | Kyle Moran | Chief Financial Officer | A | — | — |
| 2025-02-06 | Chris Francis | See Remarks | A | — | — |
| 2025-01-24 | Chandra Vargeese | See Remarks | M | — | — |
| 2024-11-27 | PAUL BOLNO | President and CEO | MIXED | — | — |
| 2024-11-15 | PAUL BOLNO | President and CEO | Sell | — | — |
| 2024-11-13 | Chris Francis | See Remarks | MIXED | — | — |
| 2024-10-18 | Chris Francis | See Remarks | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 23,157,567 | — |
| — | 10%+ Owner | 18,245,691 | — |
| — | Director | 18,203,009 | — |
| — | Director | 17,202,009 | — |
| — | Director | 9,626,487 | — |
| — | 10%+ Owner | 3,228,690 | — |
| — | Director | 2,780,480 | — |
| — | See Remarks | 411,474 | — |
| — | President and CEO | 275,520 | — |
| — | Director | 275,217 | — |
| — | Chief Financial Officer | 134,385 | — |
| — | See Remarks | 125,817 | — |
| — | See Remarks | 77,161 | — |
| — | Director | 44,930 | — |
| — | Chief Commerical Officer | 39,000 | — |
| — | Chief Financial Officer | 29,186 | — |
| — | Director | 28,815 | — |
| — | Director | 28,815 | — |
| — | Director | 27,700 | — |
| — | Director | 24,968 | — |
| — | Interim CFO | 6,392 | — |
| — | See Remarks | 4,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the WVE quote page; the site-wide leaderboard is on the insider transactions hub.